Results 201 to 210 of about 1,277,493 (295)

RNA‐Binding Protein RBM25 Targets the mRNA Stability of GTPase Rab22a to Restrict Viral Entry and Infection

open access: yesAdvanced Science, Volume 13, Issue 51, 14 September 2026.
This study identifies RNA‐binding protein RBM25 as a broad‐spectrum antiviral factor acting independently of type I interferon. It blocks viral entry by suppressing GTPase Rab22a via the RC3H1‐mediated destabilization of Rab22a mRNA. Viral downregulation of RBM25 enhances GTPase Rab22a expression and viral entry, revealing an unreported post ...
Yingying Ding   +13 more
wiley   +1 more source

Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation

open access: yesAdvanced Science, Volume 13, Issue 53, 24 September 2026.
Nab‐TAC enables targeted degradation of HBV surface antigen (HBsAg) in vivo. By fusing nanobody‐based recognition domains with programmable proteasome‐recruiting degradation signals, Nab‐TAC reduces HBsAg levels in a hydrodynamic HBV mouse model. ABSTRACT Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because
Max Yu‐Chen Pan   +11 more
wiley   +1 more source

Multidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1404-1418, September 2026.
ABSTRACT Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ ...
Hidde C. G. Overtoom   +1 more
wiley   +1 more source

Evaluating the Prognostic Relevance of Pre-Treatment Epstein-Barr Virus Levels in Non-Endemic Pediatric Nasopharyngeal Carcinoma. [PDF]

open access: yesCancers (Basel)
Farrag A   +20 more
europepmc   +1 more source

Cross‐tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Apolipoprotein E (APOE) ε4 is the strongest genetic risk factor for late‐onset Alzheimer's disease (AD), but its contribution to disease pathogenesis remains incompletely understood. METHODS Here, we integrate proteomic profiling of plasma (n = 9028), cerebrospinal fluid (n = 1099), dorsolateral prefrontal cortex (n = 720), and ...
Artur Shvetcov   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy